Boardroom Alpha
Meeting calendar
VTRS · Annual meeting · Friday, December 5, 2025

Viatris Inc

13 nominees · 3 ballot items.

Election of 13 director nominees; advisory vote to approve the 2024 compensation of Viatris' named executive officers (Say-on-Pay); and ratification of Deloitte & Touche LLP as Viatris' independent registered public accounting firm for 2025.

Market cap
$20.1B
1Y TSR
+84.7%
Board grade
C
Record date
Oct 10, 2025
Filing
DEF 14A
Meeting concluded · Dec 5, 2025

Follow how the vote landed and what changed on Viatris Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Election of 13 director nominees to hold office until the 2026 annual meeting, as recommended by the Board.

  2. 2

    Advisory Vote to Approve the 2024 Compensation of the Named Executive Officers of the Company

    ManagementBoard: FOR

    Non-binding advisory vote on the 2024 compensation of Viatris' named executive officers, as disclosed in the proxy statement.

  3. 3

    Ratification of the Selection of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025

    ManagementBoard: FOR

    Ratification of Deloitte & Touche LLP as Viatris' independent registered public accounting firm for the 2025 fiscal year.

Director elections

Nominees on the ballot13

Independent
Tenure on this board
1.2 yrs
Also a director at
Humana Inc (HUM)Zoetis Inc (ZTS)Hewlett Packard Enterprise Co (HPE)
Independent
Tenure on this board
3.5 yrs
Also a director at
Icu Medical Inc (ICUI)Mettler Toledo International Inc (MTD)
Independent
Tenure on this board
5.7 yrs
Also a director at
Genworth Financial Inc (GNW)
Independent
Tenure on this board
5.7 yrs
Also a director at
Simply Good Foods Co (SMPL)Advantage Solutions Inc (ADV)
Independent
Tenure on this board
5.7 yrs
Also a director at
Goldman Sachs Bdc Inc (GSBD)NONE
Independent
Tenure on this board
5.7 yrs
Also a director at
Omnicell Inc (OMCL)
Independent
Tenure on this board
1.2 yrs
Also a director at
Avantor Inc (AVTR)
Not independent
Tenure on this board
3.5 yrs
Also a director at
Bioatla Inc (BCAB)
Independent
Tenure on this board
2.1 yrs
Also a director at
Crinetics Pharmaceuticals Inc (CRNX)
Ownership

Top institutional holders10

Latest 13F quarter
1DAVIS SELECTED ADVISERS6.7%78,211,191$1.1B
2VANGUARD CAPITAL MANAGEMENT LLC6.4%74,716,631$1.0B
3PRICE T ROWE ASSOCIATES INC /MD/5.5%64,134,134$866M
4VANGUARD PORTFOLIO MANAGEMENT LLC4.6%53,911,237$728M
5STATE STREET CORP4.5%52,233,699$706M
6BlackRock, Inc.3.2%37,173,067$502M
7DIMENSIONAL FUND ADVISORS LP3.0%35,257,432$476M
8Rubric Capital Management LP2.9%33,500,000$453M
9GEODE CAPITAL MANAGEMENT, LLC2.4%28,087,981$379M
10BlackRock, Inc.2.1%24,665,335$333M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Viatris Inc 2025 annual meeting?
Viatris Inc (VTRS) holds its 2025 annual shareholder meeting on Friday, December 5, 2025.
What is the record date for the Viatris Inc 2025 meeting?
The record date for the Viatris Inc 2025 meeting is Friday, October 10, 2025. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Viatris Inc's 2025 meeting?
The board is presenting 13 director nominees at the Viatris Inc 2025 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Viatris Inc 2025 meeting?
Shareholders will vote on 3 proposals at the Viatris Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer